Zoetis Inc. (NYSE:ZTS) Shares Purchased by Baldwin Wealth Partners LLC MA

Baldwin Wealth Partners LLC MA grew its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 4.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 78,107 shares of the company's stock after buying an additional 3,146 shares during the quarter. Baldwin Wealth Partners LLC MA's holdings in Zoetis were worth $12,860,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of ZTS. Mission Wealth Management LP increased its position in shares of Zoetis by 2.0% in the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after purchasing an additional 59 shares during the last quarter. VeraBank N.A. increased its holdings in Zoetis by 4.1% in the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company's stock valued at $254,000 after buying an additional 62 shares during the last quarter. HUB Investment Partners LLC raised its stake in Zoetis by 4.7% in the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock valued at $224,000 after buying an additional 62 shares in the last quarter. Coppell Advisory Solutions LLC raised its stake in Zoetis by 18.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock valued at $68,000 after buying an additional 64 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators lifted its holdings in Zoetis by 6.6% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company's stock worth $170,000 after buying an additional 65 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Insider Transactions at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the sale, the executive vice president now directly owns 15,129 shares of the company's stock, valued at $2,571,930. This trade represents a 4.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.18% of the company's stock.

Wall Street Analyst Weigh In

ZTS has been the topic of several research analyst reports. Morgan Stanley cut their target price on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. UBS Group dropped their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Piper Sandler boosted their price objective on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Monday, May 12th. Barclays upped their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a report on Friday, February 14th. Finally, Stifel Nicolaus dropped their price target on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $212.75.

Zoetis Stock Performance

Shares of NYSE:ZTS traded up $2.49 during trading on Tuesday, reaching $167.10. The company had a trading volume of 2,741,141 shares, compared to its average volume of 2,545,023. The firm has a market capitalization of $74.39 billion, a price-to-earnings ratio of 30.55, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The stock's fifty day moving average price is $157.43 and its 200 day moving average price is $164.12. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. During the same period in the prior year, the business posted $1.38 EPS. The company's revenue for the quarter was up 1.4% on a year-over-year basis. As a group, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be given a dividend of $0.50 per share. The ex-dividend date is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.20%. Zoetis's payout ratio is 35.91%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.